Profile data is unavailable for this security.
About the company
AddLife AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company markets and sells instruments, equipment, consumables and related services mainly to the healthcare sector. The Company operates through two segments: The LabTech segment is engaged in the sales of laboratory equipment, analytical instruments and reagents, that are used for diagnostics or biomedical research; The MedTech segment offers various medical device equipment, consumables, instruments and devices, primarily to hospitals. The Company operates through number of subsidiaries, such as BergmanLabora AB, BioNordica group, Holm & Halby A/S, Immuno Diagnostic Oy, LabRobot Products AB, Triolab-group, Active Care Sverup AB, Fenno Medical Oy, Mediplast AB, among others.
- Revenue in SEK (TTM)10.01bn
- Net income in SEK117.00m
- Incorporated2014
- Employees2.36k
- LocationAddLife ABBrunkebergstorg 5, Box 3145STOCKHOLM 103 62SwedenSWE
- Phone+46 842003830
- Websitehttps://www.add.life/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CellaVision AB | 737.16m | 150.21m | 5.04bn | 228.00 | 33.58 | 6.57 | 26.29 | 6.84 | 6.30 | 6.30 | 30.91 | 32.19 | 0.7849 | 1.91 | 7.26 | 3,233,162.00 | 15.99 | 15.30 | 18.45 | 18.24 | 66.99 | 69.03 | 20.38 | 19.98 | 2.15 | 1,358.86 | 0.044 | 110.18 | 5.94 | 13.17 | 10.12 | 8.00 | 30.45 | 8.45 |
RaySearch Laboratories AB (publ) | 1.17bn | 175.06m | 5.17bn | 414.00 | 38.01 | 8.20 | 12.41 | 4.42 | 5.10 | 5.10 | 34.09 | 23.65 | 0.6023 | 5.51 | 3.29 | 3,005,152.00 | 9.02 | 1.29 | 13.69 | 1.88 | 91.06 | 90.57 | 14.97 | 2.55 | 1.27 | 108.61 | 0.3706 | 69.00 | 21.16 | 10.26 | 243.06 | 0.7648 | -1.31 | -- |
Surgical Science Sweden AB | 859.83m | 193.34m | 7.25bn | 270.00 | 37.48 | 1.63 | 28.79 | 8.43 | 3.79 | 3.79 | 16.85 | 87.19 | 0.1769 | 1.56 | 6.80 | 3,307,035.00 | 3.98 | 4.49 | 4.21 | 4.78 | 68.65 | 70.06 | 22.49 | 23.75 | 3.73 | -- | 0.00 | 0.00 | 10.01 | 68.14 | 24.47 | -- | 38.57 | -- |
Arjo AB (publ) | 11.18bn | 511.00m | 8.39bn | 6.85k | 17.60 | 1.14 | 5.61 | 0.7505 | 1.88 | 1.88 | 41.05 | 28.87 | 0.7149 | 4.54 | 6.78 | 1,644,896.00 | 3.26 | 3.55 | 4.62 | 5.55 | 43.64 | 44.01 | 4.56 | 5.41 | 0.626 | 3.97 | 0.4073 | 43.01 | 10.03 | 5.97 | 6.90 | 10.15 | -8.89 | 10.35 |
Revenio Group Oyj | 1.19bn | 221.01m | 8.42bn | 230.00 | 37.67 | 7.13 | 29.86 | 7.09 | 0.7204 | 0.7204 | 3.86 | 3.81 | 0.7834 | 4.93 | 8.17 | 472,574.10 | 14.67 | 14.33 | 17.09 | 17.90 | 49.29 | 50.73 | 18.72 | 21.13 | 1.51 | 34.57 | 0.1276 | 55.81 | -0.4125 | 25.80 | -12.15 | 18.72 | 17.67 | 6.30 |
Biotage AB | 2.13bn | 257.00m | 11.82bn | 675.00 | 46.02 | 3.10 | 26.99 | 5.56 | 3.21 | 3.21 | 26.56 | 47.60 | 0.4312 | 1.59 | 7.22 | 3,155,786.00 | 5.21 | 10.74 | 6.05 | 12.77 | 62.67 | 61.40 | 12.08 | 15.75 | 1.15 | 43.88 | 0.0616 | 40.11 | 19.54 | 15.50 | -8.21 | 7.97 | 14.05 | 1.30 |
ChemoMetec A/S | 635.70m | 212.41m | 12.15bn | 173.00 | 57.21 | 13.79 | 50.63 | 19.11 | 7.83 | 7.83 | 23.44 | 32.48 | 0.6112 | 0.745 | 6.97 | 2,357,630.00 | 20.42 | 27.96 | 24.40 | 35.10 | 78.80 | 79.57 | 33.41 | 35.02 | 3.76 | -- | 0.0073 | 144.08 | -8.22 | 18.37 | -23.72 | 26.64 | 9.97 | -11.81 |
Xvivo Perfusion AB | 750.59m | 204.27m | 14.08bn | 161.00 | 67.94 | 6.76 | 51.02 | 18.76 | 6.58 | 6.58 | 24.07 | 66.13 | 0.3325 | 1.14 | 4.67 | 4,691,194.00 | 9.05 | 1.24 | 9.68 | 1.33 | 74.41 | 73.14 | 27.21 | 4.76 | 4.23 | -- | 0.0117 | 0.00 | 43.88 | 26.04 | 398.29 | 48.57 | 21.35 | -- |
AddLife AB | 10.01bn | 117.00m | 15.12bn | 2.36k | 133.63 | 3.05 | 14.41 | 1.51 | 0.9601 | 0.9601 | 82.16 | 42.09 | 0.7625 | 3.50 | 5.58 | 4,351,152.00 | 0.9063 | 5.31 | 1.29 | 8.83 | 37.30 | 36.89 | 1.19 | 5.79 | 0.638 | 1.66 | 0.5146 | 31.73 | 6.62 | 31.30 | -60.42 | 8.00 | 44.43 | -1.89 |
Elekta AB (publ) | 18.12bn | 1.13bn | 22.89bn | 4.57k | 20.96 | 2.22 | 9.91 | 1.26 | 2.96 | 2.96 | 47.38 | 28.01 | 0.5822 | 3.16 | 2.89 | 3,903,469.00 | 3.65 | 4.19 | 6.53 | 7.51 | 36.76 | 39.03 | 6.27 | 7.37 | 0.7425 | 3.91 | 0.4196 | 68.60 | 7.41 | 5.98 | 38.07 | 1.68 | 20.06 | 5.92 |
Embla Medical hf | 9.26bn | 761.49m | 24.05bn | 4.00k | 31.79 | 2.78 | 17.65 | 2.60 | 1.14 | 1.14 | 13.78 | 12.98 | 0.5755 | 2.23 | 6.65 | 1,486,470.00 | 4.75 | 4.06 | 5.51 | 4.76 | 62.02 | 62.47 | 8.25 | 6.91 | 1.26 | 6.59 | 0.4074 | 3.99 | 9.33 | 5.09 | 37.34 | -6.05 | 6.50 | -- |
Vitrolife AB | 3.55bn | -3.81bn | 28.42bn | 1.10k | -- | 2.16 | -- | 8.00 | -28.10 | -28.10 | 26.24 | 97.03 | 0.1867 | 3.48 | 6.48 | 3,293,791.00 | -19.99 | -4.57 | -20.71 | -4.78 | 58.16 | 58.38 | -107.03 | -21.89 | 2.36 | 9.24 | 0.135 | -- | 8.60 | 24.99 | -1,077.41 | -- | -7.95 | 3.30 |
Holder | Shares | % Held |
---|---|---|
SEB Investment Management ABas of 31 Dec 2023 | 12.43m | 10.55% |
AMF Fonder ABas of 31 Dec 2023 | 10.10m | 8.57% |
Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 6.65m | 5.65% |
Cliens Kapitalf�rvaltning ABas of 14 Feb 2024 | 6.34m | 5.38% |
F�rsta AP-fondenas of 31 Dec 2023 | 5.50m | 4.67% |
ODIN Forvaltning ASas of 31 Oct 2024 | 4.93m | 4.18% |
The Vanguard Group, Inc.as of 06 Nov 2024 | 3.92m | 3.33% |
ODIN Forvaltning AS (Sweden)as of 28 Jun 2024 | 3.50m | 2.97% |
Fj�rde AP-fondenas of 31 Dec 2023 | 3.04m | 2.58% |
Tredje AP-fondenas of 31 Dec 2023 | 2.56m | 2.17% |